RECURRENT WALDENSTROM MACROGLOBULINEMIA
Clinical trials for RECURRENT WALDENSTROM MACROGLOBULINEMIA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT WALDENSTROM MACROGLOBULINEMIA trials appear
Sign up with your email to follow new studies for RECURRENT WALDENSTROM MACROGLOBULINEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Blood cancer transplant study tests safer GVHD prevention
Disease control TerminatedThis study looked at people with blood cancers receiving a stem cell transplant from an unrelated donor. The goal was to compare two drug combinations (cyclosporine plus sirolimus with either MMF or post-transplant cyclophosphamide) to prevent graft-versus-host disease (GVHD), a …
Matched conditions: RECURRENT WALDENSTROM MACROGLOBULINEMIA
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 17, 2026 03:55 UTC
-
Cancer drug cocktail studied for rare blood cancer
Disease control TerminatedThis study tested a combination of two drugs, ibrutinib and ixazomib, in 21 people with Waldenström macroglobulinemia, a rare blood cancer. The goal was to see if the combo could shrink tumors or stop the cancer from growing. The study was stopped early, so results are limited, b…
Matched conditions: RECURRENT WALDENSTROM MACROGLOBULINEMIA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
Experimental drug shows promise for rare blood cancer
Disease control TerminatedThis early-phase study tested the drug pomalidomide in 15 people with Waldenstrom macroglobulinemia, a rare blood cancer, that had returned or stopped responding to prior treatments. The main goal was to find the safest dose and watch for side effects. The study was stopped early…
Matched conditions: RECURRENT WALDENSTROM MACROGLOBULINEMIA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 11, 2026 20:52 UTC